The University of Michigan’s Wolverine Venture Fund, managed by the school’s business school students, is among those investors to invest in the newest round of Sonitus Medical, a medical device company that manufactures a non-surgical, removable hearing device that transmits sound via the teeth. Other participants in the $25 million Series D included Arboretum Ventures and [...]
You are browsing the archive for Novartis BioVentures - peHUB.
Akebia Therapeutics Inc., a pharmaceutical company focused on treatments for anemia, has drawn down a $4.1 million tranche of its previously announced Series B financing. Investors included Novartis Bioventures, Venture Investors, Triathlon Medical Ventures, Kearny Venture Partners, Athenian Venture Partners, Sigvion Capital and AgeChem Venture Fund.
Catalyst Biosciences Inc. has sealed a $7 million milestone payment from Pfizer, as part of a research and license agreement between the two companies. Catalyst recently initiated Phase 1 clinical trials for one of its products, designed to help treat hemophilia patients. Privately held Catalyst is backed by investors including Essex Woodlands Health Ventures, HealthCare Ventures, Johnson & Johnson Development Corporation, Morgenthaler Ventures, Novartis BioVentures, RCT BioVentures and Sofinnova Ventures.